ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,308.89
0.01%
Dow Jones
39,821.94
0.04%
US Dollar vs MXN
16.60015
0.27%
Brent Oil
82.355
-1.41%
Bitcoin
69,838.33
-2.26%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Purple Biotech Ltd (PPBT)

  7. Purple Biotech Ltd (PPBT) Noticias

PPBT Purple Biotech Ltd

0.5522
-0.01095 (-1.94%)
Última actualización: 10:47:56
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Purple Biotech Ltd PPBT NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.01095 -1.94% 0.5522 10:47:56
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.583 0.53 0.583 0.56315
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
21/5/202406:40EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/5/202406:30GLOBEPurple Biotech Reports First Quarter 2024 Financial Results
25/4/202406:00GLOBEPurple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer..
28/3/202406:00GLOBEPurple Biotech to Present New Data On its Oncology Drug..
14/3/202406:30GLOBEPurple Biotech Reports Preclinical Proof of Concept for its..
06/3/202415:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/3/202415:00EDGAR2Form 20-F - Annual and transition report of foreign private..
05/3/202406:58EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/3/202406:55GLOBEPurple Biotech Reports Fourth Quarter and Full-Year 2023..
27/2/202406:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/2/202406:00GLOBEPurple Biotech Presents Data of its Phase 1 Head & Neck..
13/2/202406:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/2/202406:00GLOBEPurple Biotech Convenes a Head & Neck Cancer Scientific..
01/2/202406:40EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202406:30GLOBEPurple Biotech Reaches Recommended Phase 2 Dose for NT219
26/1/202415:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202307:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202307:05GLOBEPurple Biotech Appoints Dr. Yael Margolin to its Board of..
14/12/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/202305:50GLOBEPurple Biotech Completes Patient Enrollment in Phase 2..
21/11/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202305:50GLOBEPurple Biotech Reports Third Quarter 2023 Financial Results
14/11/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
14/11/202315:13EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
13/11/202315:11EDGAR2Form F-1/A - Registration statement for certain foreign..
02/11/202306:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/11/202306:00GLOBEPurple Biotech Fortifies NT219 Patent Protection
30/10/202315:30EDGAR2Form F-1 - Registration statement for certain foreign..
19/10/202315:40EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
19/10/202315:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/10/202314:55GLOBEPurple Biotech Announces Closing of $5 Million Registered..
19/10/202309:36EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/10/202309:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
17/10/202307:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/10/202307:00GLOBEPurple Biotech Announces $5 Million Registered Direct..
17/10/202306:03EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/10/202306:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/10/202307:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/10/202306:50GLOBEPurple Biotech Reports Potential Biomarker Data Support..
03/10/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/10/202306:50GLOBEPurple Biotech Reports Positive Interim and Preliminary..
21/9/202307:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/9/202307:00GLOBEPurple Biotech to Present New CM24 Pancreatic Cancer..
13/9/202307:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/8/202308:29GLOBEPurple Biotech Reports Second Quarter 2023 Financial Results
22/8/202307:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/7/202307:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/7/202307:15GLOBEPurple Biotech Reports Positive Results of CM24 Dose..

Su Consulta Reciente

NASDAQ
PPBT
Purple Biotech
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados